atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced several key leadership appointments to advance its aim of delivering innovative mental health...…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies...…
…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)’ chief scientific officer Dr Srinivas Rao joined Proactive to discuss the companys latest clinical trial…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a Buy rating from Jefferies analysts as the company’s pipeline of mental health therapies...…
…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) recently welcomed encouraging results from Beckley Pystech’s Phase 1 trial of its patient-protected intravenous...…
…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech’s Phase1 trial of its patient-protected intravenous...…
Analysts at Jefferies remain bullish on atai Life Sciences (NASDAQ:ATAI, ETR:9VC) as the broader psychedelic space this week hit a “technical…
atai Life Sciences has announced the appointments of Scott Braunstein and Laurent Fischer as directors to its board. Braunstein previously…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has a pipeline of psychedelic and non-psychedelic drug assets that are poised to create value,…
Deep Dive - atai Life Sciences…
atai Life Sciences has announced Florian Brand will step down as chief executive and be succeeded by co-founder Srinivas Rao.…
atai Life Sciences has announced Florian Brand will step down as chief executive and be succeeded by co-founder Srinivas Rao.…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced co-founder Srinivas Rao will take on the CEO role following the resignation of…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that Beckley Psytech has dosed the first patient in the second part of its…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the results of investee Beckley Beckley Psytechs Phase 1 study of its novel,…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus…
…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it has enough cash, marketable securities, and a committed loan facility to support its…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has hailed positive results from its investee Beckley Psytech’s Phase 2a study of its novel…
…
SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) announces that…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first healthy participant in a Phase 1b trial evaluating its…
^* Mehrere Wirkstoffe im fortgeschrittenen klinischen Stadium der Entwicklung,
einschließlich der laufenden Phase-2b-Studie…
^NEW YORK und BERLIN, Aug. 09, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences
(NASDAQ: ATAI) (?atai"), ein…
^NEW YORK und BERLIN, June 05, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences
(https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc-
XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy-
t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu-
4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ-
krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"),
ein…
^* RL-007: Erster Patient in der Phase-IIb-Studie zu RL-007 bei kognitiver
Beeinträchtigung im…
^NEW YORK und BERLIN, May 03, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences
(https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc-
XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy-
t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu-
4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ-
krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"),
ein…
^NEW YORK und BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences
(https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc-
XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy-
t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu-
4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ-
krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"),
ein…
^NEW YORK und BERLIN, April 17, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences
(https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc-
XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy-
t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu-
4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ-
krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"),
ein…
^* Die Entwicklungskandidaten von atai, wie RL-007 und GRX-917, stellen
allesamt bedeutende Möglichkeiten…
^* RL-007: Erster Patient in der laufenden Phase-2b-Studie bei kognitiver
Beeinträchtigung im Zusammenhang…
^NEW YORK und BERLIN, March 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences
(https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc-
XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy-
t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu-
4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ-
krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"),
ein…